Freestone Grove Partners LP Acquires Shares of 41,332 Maximus, Inc. $MMS

Key Points

• Freestone Grove Partners acquired 41,332 Maximus shares worth approximately $2.22 million, while institutional investors collectively own 97.21% of the company.
• Maximus slightly beat quarterly EPS expectations at $2.22, but revenue fell 5.1% year over year to $1.28 billion and missed estimates. Fiscal 2026 EPS guidance is $7.90–$8.20, with analysts expecting $8.03.
• The company declared a quarterly dividend of $0.33, equivalent to a 2.2% annualized yield, while analyst sentiment remains cautious: ratings include “Hold” and “Strong Sell,” producing a consensus “Reduce” rating.

Freestone Grove Partners LP bought a new stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 41,332 shares of the health services provider's stock, valued at approximately $2,222,000. Freestone Grove Partners LP owned 0.08% of Maximus as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MMS. Farther Finance Advisors LLC lifted its stake in shares of Maximus by 69.0% in the 4th quarter. Farther Finance Advisors LLC now owns 284 shares of the health services provider's stock valued at $25,000 after purchasing an additional 116 shares during the last quarter. Advisory Services Network LLC bought a new position in Maximus during the third quarter valued at about $32,000. Canada Pension Plan Investment Board bought a new position in Maximus during the second quarter valued at about $35,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Maximus by 225.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 439 shares of the health services provider's stock worth $38,000 after buying an additional 304 shares during the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in shares of Maximus in the second quarter worth about $40,000. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus Price Performance

Shares of NYSE:MMS opened at $59.73 on Friday. Maximus, Inc. has a 1-year low of $52.73 and a 1-year high of $100.00. The firm has a market capitalization of $3.13 billion, a PE ratio of 8.82 and a beta of 0.59. The business's 50 day moving average is $57.66 and its 200-day moving average is $63.63. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 0.90.

Maximus (NYSE:MMS - Get Free Report) last issued its earnings results on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.33 billion. Maximus had a return on equity of 24.91% and a net margin of 7.07%.Maximus's revenue was down 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.16 earnings per share. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Sell-side analysts predict that Maximus, Inc. will post 8.03 earnings per share for the current year.

Maximus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be paid a $0.33 dividend. The ex-dividend date is Friday, August 14th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.2%. Maximus's dividend payout ratio is currently 19.50%.

Key Headlines Impacting Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Zacks raised its FY2028 EPS forecast to $9.15 from $8.94, while also increasing estimates for Q1 2028, Q2 2028 and Q3 2028. The revisions suggest expectations for longer-term earnings growth remain intact.
• Neutral Sentiment: The analyst made several offsetting changes to its forecasts, including higher estimates for Q2 2027 and lower estimates for Q1 2027, Q3 2027 and Q4 2027. Zacks projects FY2027 EPS of $8.37 and FY2028 EPS of $9.15, but retains a “Strong Sell” rating.
• Negative Sentiment: Zacks cut its FY2026 EPS estimate to $8.07 from $8.41 and reduced its Q4 2026 forecast to $1.93 from $2.29. The FY2026 estimate is only slightly above the broader consensus of $8.03, indicating limited near-term earnings upside and creating pressure on the shares.
• Negative Sentiment: The negative revisions follow Maximus’ latest quarterly results, which showed revenue below expectations and a 5.1% year-over-year decline, despite a small EPS beat. With shares still below their 200-day moving average, investors may remain focused on contracting revenue and the risk that government-services demand or contract timing could weigh on earnings.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Wall Street Zen downgraded Maximus from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research cut Maximus from a "hold" rating to a "strong sell" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Maximus in a report on Monday, August 17th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Reduce".

Maximus Company Profile

Maximus, Inc NYSE: MMS is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children's Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source